The Civica Rx Team
President & Chief Executive Officer
Martin VanTrieste is a former chief quality officer at Amgen who was recently named one of Modern Healthcare’s 100 Most Influential People in Healthcare and a leader on The Medicine Maker’s Power List of Industry Influencers. He brings over 35 years in the industry, with comprehensive experience in biopharmaceutical manufacturing, quality systems and related government regulations in the U.S. and around the world.
Under Martin’s leadership, Civica has expanded its membership to include over 50 health systems, representing over 1,350 hospitals across the U.S., and has more than 40 essential medications for hospitals, eleven of which are being used to treat COVID-19 patients. Most recently, Civica began providing its medicines to the U.S. Department of Veterans Affairs and the U.S. Department of Defense. During the peak of COVID-19 outbreaks in the U.S., Martin led efforts to deliver 2.1 million containers of Civica medicines to the country’s Strategic National Stockpile. In addition to working with quality supplier partners, Martin and the Civica team are working to advance generic drug production in the U.S. and are in the design phase for Civica’s future finished dosage generic manufacturing facility. The plant will be in Petersburg, Virginia and is part of a partnership with the U.S. Department of Health and Human Services and Phlow Corporation for end-to-end advanced manufacturing of essential medications.
Prior to joining Civica and Amgen before that, Mr. VanTrieste was with Bayer Healthcare’s Biological Products Division as vice president of worldwide quality and Abbott Laboratories as the vice president of quality assurance for the Hospital Products Division.
Mr. VanTrieste is the founder of Rx-360, an international nonprofit organization that enhances patient safety by increasing security and quality in the biopharmaceutical supply chain. He has also served as the Chairman of the Parenteral Drug Association (PDA) Board of Directors.
Mr. VanTrieste earned a Pharmacy degree from Temple University School of Pharmacy.
Chief Communications & Public Affairs Officer
With more than 25 years of experience in corporate communications and public relations agency environments, Debbi’s experience includes communications leadership roles in biopharma/healthcare, high tech, energy, government and hunger relief.
Most recently in biopharma with Alexion, Amgen, Novartis Vaccines (now GSK), and Shire (now Takeda), Debbi’s focus has been on patient-centered company narratives, media relations, corporate responsibility, employee communications, crisis and issues management, M&A communications, social media and brand creative. She has received award-winning recognition for her leadership of communications/change campaigns that helped companies solve business challenges and deliver improved and sustained results.
Debbi is a graduate of Syracuse University’s S.I. Newhouse School of Public Communications.
Russell A. Gall
Chief Manufacturing & Supply Chain Officer
Russell Gall serves on the executive leadership team of Civica Rx as Chief Manufacturing and Supply Chain Officer. Prior to Civica, Russ was actively involved in consulting throughout the pharmaceutical and medical device industry. He also currently serves on the Board of Directors of Hamlin Scientific.
As an Operations Executive with over 30 years in senior operations leadership roles in the pharmaceutical and medical device industries, Russ has had direct responsibilities for over 21 different global manufacturing sites. This has included controlled (Schedule 1-5) injectable drugs, radio-pharmaceuticals, potent compounds, cephalosporins, lyophilized products, specialty chemicals/active pharmaceutical ingredients, an extensive array of drug delivery systems, medical devices, all types of sterilization technologies, and all forms of molding and assembly operations. Russ’ functional responsibilities have included all aspects of Manufacturing, Quality, Research & Development, Supply Chain, Engineering, Maintenance, Finance, Human Resources, EH&S, Information Systems, Operational Excellence, and Contract Manufacturing.
Russ served as VP of Operations and General Manager for B. Braun Medical’s IV Solutions business in Irvine, CA, including all operations for a 1,450 employee, 4 building campus. As VP of Operations/GM for Teva Parenteral Medicines, Inc., he developed and implemented strategic plans for regulatory compliance remediation and return to market of key oncolytic products on FDA’s drug shortage list. As VP of Manufacturing Operations for Covidien, Russ led 9 global manufacturing facilities producing Contrast Media and Nuclear Medicines, generating sales of $1.1 billion. Russ was also a member of Hospira’s corporate executive team and, as VP of Operations, was responsible for the highest throughput injectable drug manufacturing site worldwide, including 2,600 employees and contributing to the generation of over $1 billion in sales.
Russ received two Bachelor of Science degrees (Microbiology and Packaging Engineering), both from Michigan State University, and is a recipient of a U.S. patent. He has also participated as a Board member of North Carolina Wesleyan College, Nash Community College Foundation, Boys & Girls Club of North Carolina, Rocky Mount Area Chamber of Commerce, and Rocky Mount Area United Way.
Chief R&D Officer
Scott Gochnour is a pharmaceutical industry leader serving on the executive leadership team with Civica Rx as the Chief Research and Development Officer. He brings extensive experience in developing and optimizing product performance and providing technical, quality and regulatory leadership to introduce quality products to market.
Prior to his position at Civica Rx, he was the Senior Vice President for Global Generic Research and Development (R&D) for Teva Pharmaceuticals, Inc. Additionally, he has held similar R&D leadership positions with Allergan, Actavis, Watson Pharmaceuticals and TheraTech for over 30 years in various research, product development, process engineering and management positions in R&D and production operations.
He was responsible for the global development and regulatory approval of both brand and generic complex dosages forms including drug/device combination products. He has had oversight for the manufacturing of pharmaceutical clinical and stability supplies in R&D pilot plants and commercial operations supporting regulatory submissions. His experience includes product formulation, process development, quality and compliance, regulatory affairs, equipment design and qualification, materials selection and evaluation, and scale-up/validation for commercial operations.
He graduated from the University of Utah with a Bachelor of Science degree in Materials Science and Engineering with emphasis in Biomaterials along with minors in Chemistry and Spanish. He is a member of the Engineering National Advisory Committee for the University of Utah and a former board member for BioUtah.
Chief Quality & Regulatory Affairs Officer
Donna’s expertise spans worldwide operations, quality, and regulatory experience across vaccine, biological, pharmaceutical and device technologies where she has held positions of significant responsibility for Quality and GxP Compliance, including various roles in drug discovery, operations, and quality and regulatory affairs at Merck & Co., Bristol Myers Squibb and Lachman Consultants.
Donna is currently the Chief Quality & Regulatory Affairs Officer at Civica, Inc., a new independent not-for-profit company founded by health care systems and philanthropies to address critical generic drug shortages caused by market failures.
Chief Financial Officer
Vikram Lamba joined Civica as Chief Financial Officer in 2018 and brings over 22 years of global experience in building healthcare companies from concept to execution. His experience in finance and M&A spans multiple international geographies and includes big pharma as well as biotech start-ups.
From 2016 to 2018, Vikram served as Chief Financial Officer & Chief Operating Officer for Fortuna Fix, a cell-therapy company in the field of regenerative medicine focused on neurodegeneration and neurotrauma. From 2011 to 2016, he served as Chief Executive Officer of Zosano Pharma Corporation and as a member of its Board of Directors. Before that, he served as Chief Financial Officer and Chief Business Officer of Predictive Biosciences, Inc. from July 2008 until he joined Zosano in 2011. Prior to that, he served as Vice President of Corporate Development at Advanced Medical Optics, Inc. (acquired by Abbott), where he was responsible for many significant merger and acquisition transactions and strategic alliances, and as Vice President for Finance and Chief Financial Officer of GeneOhm Sciences, Inc. (acquired by Becton Dickinson).
In all, Vikram has executed 25+ career deals worth more than $7 billion and managed post-merger integration for most acquisitions. He also has over 16 years of global experience in various positions with Burmah Castrol PLC and Bayer AG. During his eight years with Bayer in Canada, Germany and the U.S., he held positions in areas of general management, mergers and acquisitions and finance.
Vikram received his M.B.A. from the Asian Institute of Management and spent his final year as an exchange student at The Wharton School of the University of Pennsylvania.
Chief Business Development Officer
Ned is the Chief Business Development Officer at Civica and is primarily responsible for developing and signing long term supply partnerships to prevent drug shortages and establish fair pricing.
Prior to joining Civica, Ned worked for Abbott for 32 years, where he had a strong track record of creating successful business opportunities by developing lasting partnerships between companies that capitalized on the strengths of both. Ned closed 40+ deals worth over $2.5 billion.
While at Abbott, Ned worked in 4 business divisions: Hospital Products, Pharmaceutical Products (now AbbVie), Nutrition and Corporate Mergers and Acquisitions.
Ned was the recipient of 4 President's Awards for outstanding accomplishments and was awarded the “Biggest Contributor to Earnings Per Share” for Abbott during one year. He is an inventor with 10 issued patents.
Ned received his Bachelor and Master of Science degrees in Chemical Engineering from North Carolina State University (Raleigh, NC). He and his wife, Gail, have 3 children and reside in Dublin, Ohio.
General Counsel & Chief Compliance Officer
Jennifer is General Counsel & Chief Compliance Officer of Civica, Inc., providing strategic legal advice designed to achieve business objectives and leading a team of lawyers working closely with the segment’s business units. She has extensive experience in complex licensing, advertising, healthcare compliance and crisis management.
Prior to joining Civica, Jennifer was Senior Vice President & General Counsel, Medical Segment of Cardinal Health. Jennifer lead a global team of lawyers to support the rapidly growing Medical Segment by providing strategic legal advice, including a $6.5B acquisition of Medtronic’s Patient Recovery Business.
Before moving to Cardinal Health, Jennifer spent 15 years at Abbott. Jennifer was the head of health policy, reimbursement, managed care and strategic alliances for Abbott Nutrition. Before being asked to lead health policy, she led the legal department for the division, helping the organization navigate the challenges of being both a healthcare and consumer goods company.
Jennifer previously was with the law firm of Squire Patton Boggs.
She received a bachelor’s degree in Government from Centre College and earned a juris doctor degree from Capital University.
She and her husband, Sloan, live in New Albany, Ohio, and enjoy endless hours of watching their three sons’ sporting events. Jennifer serves on the boards of National Church Residences and the New Albany Symphony Orchestra.
Chief Commercial Officer
Heather’s expertise spans across the healthcare continuum with a focus on design, implementation and execution of hospital and health system strategies that improve patient care. Heather, one of Modern Healthcare’s “10 Women Leaders to Watch” in 2019, and a "Top 25 Women Leader" in 2021, has a 20-year plus career where she held positions of significant responsibility for strategy, operations and finance, including various roles in hospital management, quality, strategy and high-value healthcare delivery.
In 2019, Civica Rx’s first full year in operation, Heather led Civica’s Health System Membership Relationships team as it grew its membership to include over 45 health systems, representing 1,200 hospitals across the US, and delivered its first essential medications to market to address drug shortages. By December, 18 Civica medications were in production, with many more to come, thanks to ongoing team collaboration with health system pharmacy leaders and clinicians who help prioritize the medications Civica makes.
Prior to joining Civica, Heather worked at Intermountain Healthcare as an Enterprise Initiative Partner and was responsible for driving forward Intermountain’s key strategic initiatives. Before this position, Heather was the Operations Officer for Intermountain Healthcare’s LDS Hospital, with accountability for hospital-wide operations, strategic growth and high-value healthcare delivery.
Before joining Intermountain in 2008, Heather was the President / Managing Partner of Tesaris Corporation, a healthcare consulting and technology company. In this position, Heather designed and optimized strategy and operational efficiency for hospitals, ranging in size from critical access facilities to academic medical centers.
Heather received her Master of Business Administration from Arizona State University and her Bachelor of Science in Business Management from Brigham Young University.